158 related articles for article (PubMed ID: 35646656)
1. A Novel Multi-Omics Analysis Model for Diagnosis and Survival Prediction of Lower-Grade Glioma Patients.
Wu W; Wang Y; Xiang J; Li X; Wahafu A; Yu X; Bai X; Yan G; Wang C; Wang N; Du C; Xie W; Wang M; Wang J
Front Oncol; 2022; 12():729002. PubMed ID: 35646656
[TBL] [Abstract][Full Text] [Related]
2. An independently validated survival nomogram for lower-grade glioma.
Gittleman H; Sloan AE; Barnholtz-Sloan JS
Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
4. Multi-Omics Analysis Based on Genomic Instability for Prognostic Prediction in Lower-Grade Glioma.
Cao Y; Zhu H; Liu W; Wang L; Yin W; Tan J; Zhou Q; Xin Z; Huang H; Xie D; Zhao M; Jiang X; Peng J; Ren C
Front Genet; 2021; 12():758596. PubMed ID: 35069679
[No Abstract] [Full Text] [Related]
5. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
6. Radiomics-Based Method for Predicting the Glioma Subtype as Defined by Tumor Grade, IDH Mutation, and 1p/19q Codeletion.
Li Y; Ammari S; Lawrance L; Quillent A; Assi T; Lassau N; Chouzenoux E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406550
[TBL] [Abstract][Full Text] [Related]
7. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Liu Z; Zhang T; Jiang H; Xu W; Zhang J
Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
[TBL] [Abstract][Full Text] [Related]
8. An MRI-based radiomics signature as a pretreatment noninvasive predictor of overall survival and chemotherapeutic benefits in lower-grade gliomas.
Wang J; Zheng X; Zhang J; Xue H; Wang L; Jing R; Chen S; Che F; Heng X; Li G; Xue F
Eur Radiol; 2021 Apr; 31(4):1785-1794. PubMed ID: 33409797
[TBL] [Abstract][Full Text] [Related]
9. Integrated proteomic analysis of low-grade gliomas reveals contributions of 1p-19q co-deletion to oligodendroglioma.
Wong D; Lee TH; Lum A; Tao VL; Yip S
Acta Neuropathol Commun; 2022 May; 10(1):70. PubMed ID: 35526077
[TBL] [Abstract][Full Text] [Related]
10. Thin-Slice Magnetic Resonance Imaging-Based Radiomics Signature Predicts Chromosomal 1p/19q Co-deletion Status in Grade II and III Gliomas.
Kong Z; Jiang C; Zhang Y; Liu S; Liu D; Liu Z; Chen W; Liu P; Yang T; Lyu Y; Zhao D; You H; Wang Y; Ma W; Feng F
Front Neurol; 2020; 11():551771. PubMed ID: 33192984
[No Abstract] [Full Text] [Related]
11. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
12. MRI radiomics analysis of molecular alterations in low-grade gliomas.
Shofty B; Artzi M; Ben Bashat D; Liberman G; Haim O; Kashanian A; Bokstein F; Blumenthal DT; Ram Z; Shahar T
Int J Comput Assist Radiol Surg; 2018 Apr; 13(4):563-571. PubMed ID: 29270916
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of an Efficient MRI Radiomics Signature for Improving the Predictive Performance of 1p/19q Co-Deletion in Lower-Grade Gliomas.
Kha QH; Le VH; Hung TNK; Le NQK
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771562
[TBL] [Abstract][Full Text] [Related]
14. Behavior-Oriented Nomogram for the Stratification of Lower-Grade Gliomas to Improve Individualized Treatment.
Wei RL; Zhang LW; Li JG; Yang FD; Xue YK; Wei XT
Front Oncol; 2020; 10():538133. PubMed ID: 33392065
[TBL] [Abstract][Full Text] [Related]
15. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas.
Wu S; Zhang X; Rui W; Sheng Y; Yu Y; Zhang Y; Yao Z; Qiu T; Ren Y
Eur Radiol; 2022 May; 32(5):3187-3198. PubMed ID: 35133485
[TBL] [Abstract][Full Text] [Related]
16. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
[TBL] [Abstract][Full Text] [Related]
17. Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma.
Lin W; Qiu X; Sun P; Ye Y; Huang Q; Kong L; Lu JJ
Mol Ther Oncolytics; 2021 Jun; 21():288-302. PubMed ID: 34141867
[TBL] [Abstract][Full Text] [Related]
18. Multi-parametric Z-spectral MRI may have a good performance for glioma stratification in clinical patients.
Su C; Xu S; Lin D; He H; Chen Z; Damen FC; Ke C; Lv X; Cai K
Eur Radiol; 2022 Jan; 32(1):101-111. PubMed ID: 34272981
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive Determination of
Bhandari AP; Liong R; Koppen J; Murthy SV; Lasocki A
AJNR Am J Neuroradiol; 2021 Jan; 42(1):94-101. PubMed ID: 33243896
[TBL] [Abstract][Full Text] [Related]
20. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
